Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic lymphocytic leukemia Age: Adult |
Dose: Intravenous – 100 mg/m2 Frequency: infused over 30-60 minutes on days 1 and 2 of a 28-day cycle Duration: up to 6 cycles Note: For severe hematological or non-hematological toxicity, reduce dose to 50 mg/m2 on days 1 and 2 of each cycle. If severe hematological toxicity recurs, further reduce the dose to 25 mg/m2 on days 1 and 2 of each cycle. May consider dose re-escalation in subsequent cycles. |
|
Indication: Multiple myeloma Age: Adult |
Dose: Intravenous – 120-150 mg/m2 Frequency: infused over 30-60 minutes on days 1 and 2 of a 28-day cycle Note: Intravenous or oral prednisone may be given at a dose of 60 mg/m2 on days 1-4 of the cycle. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: No approved pediatric dosage available Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild-to-moderate |
Dose: Dose: Note: Use caution |
|
Condition: Creatinine Clearance less than 40 mL/min |
Dose: Dose: Note: Not recommended |
Administration
- Given as intravenous infusion
- Must be administered by healthcare professionals
Side Effect
- Lymphopenia (68-99%)
- Leukopenia (61-94%
- grade 3/4
- 28-56%)
- Anemia (88-89%
- grades 3/4 11-13%)
- Thrombocytopenia (77-86%
- grade 3/4
- 11-25%)
- Neutropenia (75-86%
- grade 3/4
- 43-60%)
- Nausea (20-75%)
- Fatigue (9-57%)
- Vomiting (16-40%)
- Diarrhea (9-37%)
- Bilirubin increased (Less than 34%
- grade 3/4
- 3%)
- Constipation (Less than 29%)
- Fever (24-34%)
- Pyrexia (24%)
- Anorexia (Less than 23%)
- Cough (4-22%)Headache (Less than 21%)
- Weight loss (7-18%)
- Dehydration (Less than 16%)
- Rash (8-16%)
- Stomatitis (Less than 15%)
- Back pain (Less than 14%)
- Dizziness (Less than 14%)
- Chills (6-14%)
- Peripheral edema (13%)
- Abdominal pain (5-13%)
- Insomnia (Less than 13%)
- Dyspepsia (Less than 11%)
- Weakness (8-11%)
- Upper respiratory infection (10%)
- Gastroesophageal reflux disease (Less than 10%)
- Urinary Tract Infection (UTI) (Less than 10%)
- Xerostomia (9%)
- Hypokalemia (Less than 9%)
- Anxiety (8%)
- Hyperuricemia (Less than 7%)
- Tachycardia (Less than 7%)
- Taste alteration (Less than 7%)
- Arthralgia (Less than 6%)
- Chest pain (Less than 6%)
- Depression (Less than 6%)
- Hypotension (Less than 6%)
- Injection site pain (Less than 6%)
- Pain (Less than 6%)
- Pruritus (5-6%)
- Febrile neutropenia (3-6%)
- Rash (5%)
- Myelosuppression
- tumour lysis syndrome which may lead to acute renal failure
- infections (eg sepsis
- pneumonia
- septic shock)
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- Rarely
- severe anaphylatic and anaphylactoid reactions
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP1A2 inhibitors (e.g. ciprofloxacin, fluvoxamine)
|
May increase plasma levels
|
|
CYP1A2 inducers (e.g. omeprazole and tobacco smoking)
|
May reduce plasma levels
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Drug Hypersensitivity
|
Risk of severe allergic reaction
|
|
Jaundice
|
Risk of liver complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 25° C, prior to reconstitution. Protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.